ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
I'm PortAI, I can summarize articles.
Kirby McInerney LLP is investigating Anika Therapeutics, Inc. (NASDAQ:ANIK) for potential violations of federal securities laws following a press release on July 30, 2025, regarding the clinical trial results of Hyalofast. The trial did not meet its primary endpoints, leading to a 27.42% drop in Anika's share price. Investors who acquired Anika securities are encouraged to contact the law firm for more information about their rights and the investigation.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments